usdaed

The Trade Desk (TTD) lost 37% of its value-roughly the same percentage of my faith in humanity that evaporated during my last family Zoom call. Revenue growth slowed to 19%, which sounds decent until you realize their previous CFO had held the job since the Obama administration. The new hire started on August 21st, which feels like trying to learn the alphabet while being chased by wolves. Meanwhile, stricter privacy rules loom like a neighbor who won’t stop borrowing your hedge trimmer and returning it broken.

Amazon, that most enterprising of merchants, has long mastered the art of transformation. From peddling wares to pioneering cloud services, it has become a colossus, its AWS division a titan in the realm of digital infrastructure. Yet what is AWS but the scaffolding for its latest folly? Artificial intelligence, that modern philosopher’s stone, is now its chosen muse. One might almost pity the poor robots laboring in warehouses, their toil justified by the promise of ever-faster deliveries-a farce of efficiency where the only true profit is in spectacle.

TSMC holds 90% of the advanced semiconductor market with the effortless dominance of a poet composing sonnets. While rivals fumble with antiquated quills, TSMC crafts 5nm chips with the delicacy of a calligrapher’s stroke. Their 2nm wafers, now entering production, reduce transistors to such absurdity that even Democritus might blush at the audacity of their atomic minimalism.

The XRP Ledger, that most solemn of ledgers, presents itself as the financial world’s chaperone – a bastion of “authorized trust lines” and “funds freezes,” where even tokenized real-world assets must don tuxedos and present their credentials. One might mistake it for a Parisian opera house, where the ushers inspect every patron’s pedigree before allowing them to take their seats.

On a recent occasion, the stage was set for Viking, yet the audience buzzed with discontent as news of mediocre phase 2 results regarding the oral GLP-1 weight management potion known as VK2735 swept through the theater of public opinion. Alas! But a closer examination of the script reveals a tale with merit: in a mere thirteen weeks, participants shed an average of 12.2% of their corporeal burdens-a marvel, indeed! To add salt to the wounds of comparison, the esteemed Eli Lilly saw a less impressive 12.4% weight reduction after a lengthy saga of seventy-two weeks.

Yet the analysts, those scribes of the financial realm, scrawl unanimous verdicts of “buy” upon their parchment. Their average price target aligns with the stock’s present trajectory, as if guided by an invisible hand manipulating both market and metric. How reconcile this with the grotesque ratios? How explain the dissonance between the numbers’ screaming faces and the quiet confidence of those who parse them?